Kanyos Bio Inc.
- Address
- 50 Hampshire Street Ste 402
Sponsor Overview
Specializations
Gastroenterology and Immune-Mediated Intestinal Disease
Kanyos Bio Inc. focuses on celiac disease, with clinical research centered on the intestinal consequences of gluten exposure and the protection of duodenal mucosa. Its work reflects interest in restoring normal small bowel structure and limiting disease-related tissue injury.
- Duodenal histology
- Villus-height:crypt depth ratio
- Gluten challenge
The sponsor’s clinical activity is directed toward measuring changes in intestinal architecture associated with gluten-triggered disease activity in celiac disease.
Autoimmune Disease and Antigen-Specific Tolerance
The company’s research landscape includes therapies aimed at modifying the immune response to dietary gluten in celiac disease. This places emphasis on immune tolerance and disease-specific control of inflammatory injury in the gastrointestinal tract.
- Gluten-driven immune activation
- Antigen-specific therapy
- Inflammatory mucosal injury
Clinical interest is concentrated on reducing the pathological response to gluten exposure while preserving intestinal integrity.
Translational Medicine in Digestive Tract Repair
Kanyos Bio Inc. investigates therapeutic approaches that connect immune modulation with measurable recovery in the upper small intestine. Its trial activity reflects a focus on linking treatment effects to structural markers of tissue improvement in the gut.
- Mucosal healing
- Intestinal epithelial recovery
- Structural biomarkers
Research is oriented toward understanding how treatment may influence the visible and functional consequences of gluten sensitivity within the intestinal lining.
Rare Disease Focus in Specialty Therapeutics
The sponsor’s current clinical portfolio is narrowly centered on a single celiac disease program, indicating a concentrated interest in specialty care for a chronic immune-related condition. The development effort is aligned with therapeutic options for patients who continue to experience gluten-associated intestinal damage.
- Chronic gluten sensitivity
- Specialty gastrointestinal care
- Immune-mediated enteropathy
Its research activity is directed at clinically relevant outcomes in a disease area with limited targeted treatment options.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy, Safety, and Tolerability of KAN-101 in Celiac Disease: A Phase 2a Double-Blind, Placebo-Controlled Trial |  Finland Ireland Poland The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 18 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases1 trial322 other sponsors
Partnered Research Centres
18 centres- Address
- Albert Schweitzerplaats 25, 3318 AT Dordrecht
- Address
- Beaumont Road, Beaumont, D09 V2N0 Dublin
- Address
- Ul. Mokra 4, 91-034 Lodz
- Address
- Ul. Tadeusza Szafrana 5d / U2-U5, 30-363 Krakow
- Address
- Itainen Pitkakatu 4b, 20520 Turku
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Kanyos Bio Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.